Becoming a worm

Sequencing of the worm genome has allowed Hill et al. to design oligonucleotide arrays representing 18,791 (98%) of the predicted worm open reading frames (ORFs). In the 27 October Science, they report the use of these arrays to analyze transcripts from six developmentally staged worm populations from eggs to adults (Science 2000, 290:809-812). Only 56% of the ORFs are detected at least once, suggesting that others are missed because they are expressed at very low levels in specific tissues or u

By | October 31, 2000

Sequencing of the worm genome has allowed Hill et al. to design oligonucleotide arrays representing 18,791 (98%) of the predicted worm open reading frames (ORFs). In the 27 October Science, they report the use of these arrays to analyze transcripts from six developmentally staged worm populations from eggs to adults (Science 2000, 290:809-812). Only 56% of the ORFs are detected at least once, suggesting that others are missed because they are expressed at very low levels in specific tissues or under specific conditions. Aging worms show transcriptional correlates of impaired muscle function, reduced metabolic activity and extracellular matrix defects. During development, expression of genes specific to worms becomes more predominant, at the expense of expression of genes that are evolutionarily conserved.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech